Anti-claudin 18.2 and Anti-4-1BB bispecific antibodies and uses thereof

MYPI2025000579A0Undetermined Publication Date: 2021-02-12I MAB BIOPHARMA CO LTD +1
0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025000579
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Filing Date
2020-08-12
Publication Date
2021-02-12
Patent Text Reader

Abstract

ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.
Need to check novelty before this filing date? Find Prior Art